Sugi Predict

Sugi Predict / Compounds / SCHEMBL376385

SCHEMBL376385

SCHEMBL376385

CCCC[Sn](CCCC)(CCCC)c1cnc2ccccn12

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ MAPT P10636 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ GGPS1 O95749 1/20 0.36
▸ FDPS P14324 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ MIF P14174 1/20 0.35
▸ IRAK4 Q9NWZ3 2/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ PIK3CA P42336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23089396 0.79 CYP11B1 (0.35) FLT3KDM4E
SCHEMBL19437858 0.79 CDK8 (0.41) ADORA3MAPTDYRK1A
SCHEMBL20479677 0.78 TBXAS1 (0.35) —
SCHEMBL6218692 0.76 BACE1 (0.40) KDM4EDYRK1APKM
SCHEMBL30705250 0.75 PRMT5 (0.33) —
SCHEMBL24086874 0.71 TLR7 (0.50) NPSR1MAPTFLT3KDM4ETDP1
SCHEMBL3847848 0.70 CLK1 (0.35) FLT3
SCHEMBL12801878 0.69 GGPS1 (0.50) ADORA3NPSR1MAPTFLT3KDM4E
SCHEMBL14161886 0.69 MAPT (0.46) NPSR1MAPTFLT3KDM4ETDP1
SCHEMBL14161883 0.69 MAPT (0.56) ADORA3MAPTKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 — — EP disclosed
US-20260109697-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2026-04-23 — — US disclosed
US-12215105-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2025-02-04 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-11548890-B1 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2023-01-10 — — US disclosed
CN-114945366-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2022-08-26 — — CN disclosed
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2022-08-25 — — US disclosed
EP-4027995-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-07-20 — — EP disclosed
EP-4003992-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL) -PYRIMIDINE DERIVATIVES Merck Patent GmbH (DE) 2022-06-01 — — EP disclosed
US-11078201-B2 Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists Nimbus Saturn, Inc. (US) 2021-08-03 — — US disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 — — US disclosed
US-8518952-B2 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors PFIZER INC. (US) 2013-08-27 — — US disclosed
WO-2013030138-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 — — WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 — — US disclosed
EP-2328890-B1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER (US) 2012-01-25 — — EP disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 — — US disclosed
EP-2328890-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS Pfizer Inc. (US) 2011-06-08 — — EP disclosed
EP-2231653-A1 ANTIBACTERIAL CONDENSED THIAZOLES Biota Europe Ltd (GB) 2010-09-29 — — EP disclosed
WO-2010016005-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC. (US) 2010-02-11 — — WO disclosed
WO-2009074812-A1 ANTIBACTERIAL CONDENSED THIAZOLES PROLYSIS LTD (GB) 2009-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548890-B1 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 ADORA3 3903/4885NPSR1 2913/4885MAPT 3895/4885
US-20260109697-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES CHUK, CNKSR1, KIT ADORA3 600/4885NPSR1 1736/4885MAPT 4876/4885
US-20220267320-A1 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES NCOA3, NCOR1, NCOA4 ADORA3 737/4885NPSR1 826/4885MAPT 4822/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 ADORA3 3903/4885NPSR1 2913/4885MAPT 3895/4885
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 ADORA3 4738/4885NPSR1 1736/4885MAPT 3736/4885
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS CHKA, CSNK1A1, CHKB ADORA3 4500/4885NPSR1 4242/4885MAPT 4388/4885
US-11078201-B2 Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists HIPK1, PDXK, IP6K1 ADORA3 2919/4885NPSR1 1894/4885MAPT 3099/4885
US-12215105-B2 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 ADORA3 3903/4885NPSR1 2913/4885MAPT 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.